455 related articles for article (PubMed ID: 12559222)
1. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
[TBL] [Abstract][Full Text] [Related]
2. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
[TBL] [Abstract][Full Text] [Related]
3. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of levosimendan in patients with acute heart failure.
Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.
Follath F; Cleland JG; Just H; Papp JG; Scholz H; Peuhkurinen K; Harjola VP; Mitrovic V; Abdalla M; Sandell EP; Lehtonen L;
Lancet; 2002 Jul; 360(9328):196-202. PubMed ID: 12133653
[TBL] [Abstract][Full Text] [Related]
6. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.
de Lissovoy G; Fraeman K; Teerlink JR; Mullahy J; Salon J; Sterz R; Durtschi A; Padley RJ
Eur J Health Econ; 2010 Apr; 11(2):185-93. PubMed ID: 19582491
[TBL] [Abstract][Full Text] [Related]
7. [Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine].
Oliveira MT; Follador W; Martins ML; Canaviera R; Tsuji RL; Scipioni A; Barretto AC
Arq Bras Cardiol; 2005 Jul; 85(1):9-14. PubMed ID: 16041448
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy.
Lucioni C; D'Ambrosi A; Mazzi S; Pollesello P; Apajasalo M; Fedele F
Adv Ther; 2012 Dec; 29(12):1037-50. PubMed ID: 23233357
[TBL] [Abstract][Full Text] [Related]
9. Levosimendan: a review of its use in the management of acute decompensated heart failure.
Innes CA; Wagstaff AJ
Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
[TBL] [Abstract][Full Text] [Related]
10. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
[TBL] [Abstract][Full Text] [Related]
11. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
Cavusoglu Y
Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
[TBL] [Abstract][Full Text] [Related]
12. Levosimendan compared with dobutamine in low output patients.
Nieminen MS
Minerva Anestesiol; 2003 Apr; 69(4):258-63. PubMed ID: 12766717
[TBL] [Abstract][Full Text] [Related]
13. Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case.
Mardiguian S; Kivikko M; Heringlake M; Smare C; Bertranou E; Apajasalo M; Pollesello P
J Med Econ; 2016; 19(5):506-14. PubMed ID: 26707159
[TBL] [Abstract][Full Text] [Related]
14. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
Duman D; Palit F; Simsek E; Bilgehan K; Sacide A
Can J Cardiol; 2009 Oct; 25(10):e353-6. PubMed ID: 19812809
[TBL] [Abstract][Full Text] [Related]
15. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
Schumann J; Henrich EC; Strobl H; Prondzinsky R; Weiche S; Thiele H; Werdan K; Frantz S; Unverzagt S
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009669. PubMed ID: 29376560
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
Kivikko M; Lehtonen L
Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
Mebazaa A; Nieminen MS; Filippatos GS; Cleland JG; Salon JE; Thakkar R; Padley RJ; Huang B; Cohen-Solal A
Eur J Heart Fail; 2009 Mar; 11(3):304-11. PubMed ID: 19158152
[TBL] [Abstract][Full Text] [Related]
18. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
[TBL] [Abstract][Full Text] [Related]
19. [The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome].
Levin RL; Degrange MA; Porcile R; Salvagio F; Blanco N; Botbol AL; Tanus E; del Mazo CD
Rev Esp Cardiol; 2008 May; 61(5):471-9. PubMed ID: 18462650
[TBL] [Abstract][Full Text] [Related]
20. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
Huang X; Lei S; Zhu MF; Jiang RL; Huang LQ; Xia GL; Zhi YH
J Zhejiang Univ Sci B; 2013 May; 14(5):400-15. PubMed ID: 23645177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]